

Drug Discovery Ecosystem Summit

Novartis commits to reimagining medicine



**Leo Lee, President and Representative
Director of Novartis Pharma K.K.**

July 30, 2024

 **NOVARTIS** | Reimagining Medicine



Novartis is reimagining medicine to improve and extend people's lives



xRNA



Cell & Gene Therapy



Radioligand Therapy

Providing our innovative medicines
 **284mn** **130**
patients countries

R&D spending
 **\$11.3bn**
approx. 25% of annual sales

 **Japan** is one of the 4 priority geographics

We are delivering these innovative treatments to patients in Japan

Novartis has invested in Japan to bring innovative treatments to patients

Radioligand Therapy

Investing **\$100mn**
in manufacturing facility in Sasayama



Research collaboration with
Japanese academia / bio-venture



Pediatric & Orphan Indication

*The number of approvals in Japan
in the last 5 years*

Pediatric **6**/₃₄^{*1}

Orphan **15**/₃₄^{*1}

*1 : # of approval in Japan from 2019-2023


Innovation from Japan

*Contributed to the development of
the world's first oral multiple sclerosis
treatment with a substance
originating in Japan with academia*



*2: Ref. Novartis Annual Report 2018

Novartis contributes to building a sustainable drug discovery ecosystem to fuel Japan's growth



Thank you